Rick Chapman | Director of Health Economics
Institute for Clinical and Economic Review

Rick Chapman, Director of Health Economics, Institute for Clinical and Economic Review

As Director of Health Economics at ICER, Rick directs the development of economic evaluations to accompany rigorous reviews of clinical evidence, assessing the potential costs, cost-effectiveness, and budgetary impact of a wide range of diagnostic, prognostic, therapeutic and other clinical interventions. Before coming to ICER, Rick was a Vice President of Health Economics and Outcomes Research at Avalere Health, directing the design and analysis of economic evaluations and health outcomes studies. Prior to that, Rick Chapman was a principal in the Health Economics and Outcomes Research practice at IMS Consulting Group. He was also the US regional lead for the Retrospective Database Analysis Center of Excellence at IMS, where he was responsible for conducting studies using several types of real world observational data (including medical and pharmacy administrative claims, electronic medical records, laboratory data, and registries). Previously, Rick was a senior director at ValueMedics Research LLC, which IMS acquired in 2007. Prior to joining ValueMedics, he was a research associate at the Center for Risk Analysis at the Harvard School of Public Health. Before his time at the Harvard School of Public Health, Rick conducted research on the practice of transfusion medicine as part of a National Heart, Lung, and Blood Institute Specialized Center of Research at the Center for Blood Research in Boston. Rick holds a PhD in health policy with a concentration in decision sciences from Harvard University. He also holds an MS in health policy and management from the Harvard School of Public Health, where he investigated the association between quality of care and health-care financing mechanisms.


World Orphan Drug Congress USA 2018 - Conference Day Two @ 11:15

Proposed Value based frameworks for pricing and reimbursement of orphan drugs - can a new value framework help ease friction over orphan drug prices?

  • Methods to recommend fair prices to allow for broader insurance coverage for innovative new treatments
  • Different proposals for gene therapy pricing and possible routes for implementation 
  • Impact of willingness to pay thresholds in the US and the orphan market space 

back to speakers